Beijing Business News (Reporter Ding Ning) On the evening of May 26,playgamesforrealmoneynodeposit, Baili Tianheng (688506) issued an announcement stating that the company independently researched and developedplaygamesforrealmoneynodepositThe Phase III clinical trial of the innovative biopharmaceutical injection BL-M07D1 (HER2-ADC) single agent for locally advanced or metastatic HER2-positive breast cancer has recently completed the enrollment of the first subject.
The announcement shows that BL-M07D1 is an ADC drug targeting HER2, and its indications are solid tumors such as breast cancer, gastric cancer, non-small cell lung cancer, gynecological tumors, and urinary system tumors.
